Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term study of TAK-536 in hypertensive children 2 to <6 years
jRCT2041200083Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azilsartan in hypertension (HTN), sponsored by Takeda. Primary endpoints: Number of participants who experienced at least one treatment-emergent adverse event (TEAE), Number of participants with TEAE related to resting 12-lead electrocardiograms (ECG) and 3 more. Started May 2021; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2041200083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200083.